HTG Molecular Diagnostics (HTGM) Downgraded by ValuEngine

HTG Molecular Diagnostics (NASDAQ:HTGM) was downgraded by ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued on Thursday.

A number of other brokerages also recently weighed in on HTGM. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of HTG Molecular Diagnostics in a research note on Friday, September 28th. Cantor Fitzgerald began coverage on HTG Molecular Diagnostics in a research note on Thursday, September 20th. They issued a “buy” rating and a $7.00 price objective on the stock. Zacks Investment Research downgraded HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Leerink Swann reissued an “outperform” rating on shares of HTG Molecular Diagnostics in a research note on Monday, July 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $6.25.

Shares of HTGM stock opened at $3.69 on Thursday. The company has a current ratio of 9.50, a quick ratio of 9.29 and a debt-to-equity ratio of 0.35. HTG Molecular Diagnostics has a twelve month low of $1.71 and a twelve month high of $5.83. The company has a market capitalization of $143.53 million, a P/E ratio of -2.06 and a beta of 1.78.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings data on Thursday, August 9th. The medical research company reported ($0.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.05. HTG Molecular Diagnostics had a negative return on equity of 132.67% and a negative net margin of 81.10%. The business had revenue of $4.91 million for the quarter, compared to the consensus estimate of $5.30 million. On average, research analysts forecast that HTG Molecular Diagnostics will post -0.7 EPS for the current year.

Several hedge funds have recently modified their holdings of the stock. New York State Common Retirement Fund bought a new position in HTG Molecular Diagnostics in the 1st quarter worth approximately $170,000. Northern Trust Corp bought a new position in HTG Molecular Diagnostics in the 1st quarter worth approximately $189,000. BlackRock Inc. increased its position in HTG Molecular Diagnostics by 322.8% in the 2nd quarter. BlackRock Inc. now owns 73,044 shares of the medical research company’s stock worth $238,000 after buying an additional 55,769 shares during the period. Stifel Financial Corp bought a new position in HTG Molecular Diagnostics in the 1st quarter worth approximately $343,000. Finally, Acadian Asset Management LLC bought a new position in HTG Molecular Diagnostics in the 2nd quarter worth approximately $353,000. 48.29% of the stock is currently owned by institutional investors and hedge funds.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.

See Also: What are the Benefits of Index Funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply